<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04527666</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-ANTICO-JAK2</org_study_id>
    <nct_id>NCT04527666</nct_id>
  </id_info>
  <brief_title>Anticoagulation in Gastroesophageal Varices and JAK2 Mutation</brief_title>
  <official_title>Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia,&#xD;
      and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life,&#xD;
      morbidity, and mortality of MPN patients mainly depend on disease-related symptoms,&#xD;
      thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has&#xD;
      a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of&#xD;
      this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and&#xD;
      gastroesophageal varices.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of portal vein thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>The changes of portal vein thrombosis including progression, disappear or unchanged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of variceal bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>The occurrence of variceal bleeding including haematemesis and melena</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastroesophageal Varices</condition>
  <condition>JAK2 Mutation</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Anticoagulation group</arm_group_label>
    <description>Patients with JAK2 mutation and gastroesophageal varices receive anticoagulation agents.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients with JAK2 mutation and gastroesophageal varices who didn't receive anticoagulation agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anticoagulation Agents</intervention_name>
    <description>Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.</description>
    <arm_group_label>Anticoagulation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with gastric and/or esophageal varices and JAK2 mutation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18-75&#xD;
&#xD;
          -  diagnosed as portal hypertension by contrast-enhanced computed tomography&#xD;
&#xD;
          -  diagnosed as JAK2 positive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  not had portal contrast-enhanced computed tomography&#xD;
&#xD;
          -  not had JAK2 mutation test&#xD;
&#xD;
          -  other factors judged by the investigator that may affect the safety of the subject or&#xD;
             the compliance of the trial. Such as serious illnesses (including mental illness) that&#xD;
             require combined treatment, serious laboratory abnormalities, or other family or&#xD;
             social factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaoquan HUANG, Ph.D</last_name>
    <phone>18801733835</phone>
    <email>huang.xiaoquan@zs-hospital.sh.cn</email>
  </overall_contact>
  <reference>
    <citation>Greenfield G, McMullin MF. Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series. Thromb J. 2018 Dec 19;16:33. doi: 10.1186/s12959-018-0187-z. eCollection 2018.</citation>
    <PMID>30574023</PMID>
  </reference>
  <reference>
    <citation>Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):e1-5. doi: 10.1016/j.clml.2014.04.004. Epub 2014 Jun 11.</citation>
    <PMID>25027569</PMID>
  </reference>
  <reference>
    <citation>Magaz M, Alvarez-Larrán A, Colomer D, López-Guerra M, García-Criado MÁ, Mezzano G, Belmonte E, Olivas P, Soy G, Cervantes F, Darnell A, Ferrusquía-Acosta J, Baiges A, Turon F, Hernández-Gea V, García-Pagán JC. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. J Hepatol. 2021 Jan;74(1):89-95. doi: 10.1016/j.jhep.2020.06.045. Epub 2020 Jul 15.</citation>
    <PMID>32679300</PMID>
  </reference>
  <results_reference>
    <citation>Reilly CR, Babushok DV, Martin K, Spivak JL, Streiff M, Bahirwani R, Mondschein J, Stein B, Moliterno A, Hexner EO. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. Am J Hematol. 2017 Sep;92(9):909-914. doi: 10.1002/ajh.24798. Epub 2017 Jul 26.</citation>
    <PMID>28543980</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 23, 2020</study_first_submitted>
  <study_first_submitted_qc>August 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>XiaoquanHUANG</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>portal hypertension</keyword>
  <keyword>gastroesophageal varices</keyword>
  <keyword>jak2 mutation</keyword>
  <keyword>myeloproliferative neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

